Published date: 5 October 2021

Last edited date: 9 December 2021

Closed early engagement


Closing date: 31 March 2022

Contract summary

Industry

  • Pharmaceutical products - 33600000

Location of contract

SW1H 0EU

Procurement reference

CF-0367000D0O000000rwimUAA2

Published date

5 October 2021

Closing date

31 March 2022

Contract type

Supply contract

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

Description

DHSC invites suppliers to submit an EOI on neutralising antibodies and
binding site, clinical trials on efficacy, safety
for preventing or treating COVID-19
infection, dose&frequency, formats/routes
for administering to patients, monitoring
adverse affects, efficacy against SARSCoV-
2 variants, supply availability for 2021-
2022 and future years and plans for
regulatory approval in the UK, if not yet
approved.

**Updated information on 9th December 2021**

The Therapeutics Taskforce is responsible for the end-to-end provision of treatments for COVID-19 in the UK, from the initial identification of potential therapeutics, to trialing treatments as part of an advanced programme of clinical trials, and their eventual deployment at scale to the patient population. These safe and effective treatments are vital for lessening the severity and impact of COVID-19 in individuals and communities. The Taskforce is seeking to gather information in respect of neutralising antibodies that can be deployed in a hospital or community setting. Therapeutics suppliers must provide evidence of their therapies' potential efficacy and progress in trials, monitoring and safety.

The market engagement will take the form of a webinar held on Thursday 16th December 2021. The webinar will take interested suppliers through the requirement outlined in this Prior Information Notice and will provide an opportunity for suppliers to ask questions. To sign up to join the webinar please visit: https://www.eventbrite.co.uk/e/prior-information-notice-antiviral-drug-supply-for-covid-19-webinar-tickets-225298643307 We are inviting suppliers to register their interest in the PIN by downloading a questionnaire via the Atamis platform, and sending a completed version to http://health.atamis.co.uk by 13:00 on 23rd December 2021. Responses to this questionnaire will be kept in confidence and will inform the Taskforce's market research. Suppliers are not required to fill out a questionnaire before attending the webinar. Any information shared in the webinar will be shared with all suppliers via the Atamis platform after the market engagement period associated with this PIN closes on Thursday 23rd December 2021.

More information

Previous notice about this procurement

Call for information/EOI for neutralising antibodies.

  • Early engagement
  • Published 5 October 2021

About the buyer

Contact name

Amjad Kazmi

Address

39 VICTORIA STREET
LONDON
SW1H 0EU
GB

Email

amjad.kazmi@dhsc.gov.uk